Depixus raises €30.6m in Series A financing
French-British magnetic trap specialist Depixus has raised €30,6m to develop a commercial instrument based on the company’s MAGNA technology.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2066 entries already.
Entries by Thomas Gabrielczyk
Ichnos Sciences in licence deal with Almirall
Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.
Vifor Pharma Ltd to be acquired for CHF10.9bn
Biologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn.
Fapon Biotech Races to Introduce Omicron Neutralizing Antibodies Titer Testing Solution
Given Omicron Varinat’s potential higher rate of transmissibility, Fapon Biotech has successfully introduced SARS-CoV-2 Omicron Variant Neutralizing Antibody Titer Testing Solution (ELISA) to effectively evaluate the immune evasiveness and vaccine effectiveness on Omicron varian.
Apogenix gets €25.8m cash injection for asunercept
German Apogenix AG has received a €26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.
British Adendra Therapeutics closes $53m financing
The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).
Accelerating biologics development
Abstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:
Accelerating biologics development
Abstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:
Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)
Sino Biological, Inc. announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.
Influenza Vaccine Strains
ANTIGENS Seasonal flu is a common infectious disease of the respiratory tract caused by influenza virus. There are four types of influenza virus, influenza type A, B, C, and D. The A and B types are of most interest to the medical community because they are the culprits for seasonal epidemics. Occasionally, influenza A, like the A/California/04/09 (H1N1) and A/Hong Kong/1/1968 (H3N2), can even cause global pandemics.